Resources from the same session
714MO - Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): Results from the phase II TROPION-PanTumor03 study
Presenter: Ana Oaknin
Session: Mini oral session 2: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
715MO - Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study
Presenter: Danbo Wang
Session: Mini oral session 2: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
716MO - Efficacy and safety of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer
Presenter: Xiaohua Wu
Session: Mini oral session 2: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
717MO - SHR-A1921 in platinum-resistant ovarian cancer (PROC): data from a first-in-human (FIH) phase I study
Presenter: Dihong Tang
Session: Mini oral session 2: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant 714MO, 715MO, 716MO and 717MO
Presenter: Kathleen Moore
Session: Mini oral session 2: Gynaecological cancers
Resources:
Slides
Webcast
718MO - Mirvetuximab soravtansine (MIRV) in recurrent platinum-sensitive ovarian cancer (PSOC) with high folate receptor-alpha (FRα) expression: Results from the PICCOLO trial
Presenter: Angeles Secord
Session: Mini oral session 2: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
719MO - A phase I/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer
Presenter: Elizabeth Lee
Session: Mini oral session 2: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant 718MO and 719MO
Presenter: Antonio González-Martín
Session: Mini oral session 2: Gynaecological cancers
Resources:
Slides
Webcast
720MO - IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced gynecological cancers (Gynecol C): Results from a phase I study
Presenter: Jin Shu
Session: Mini oral session 2: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
721MO - Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: A novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors
Presenter: Gottfried Konecny
Session: Mini oral session 2: Gynaecological cancers
Resources:
Abstract
Slides
Webcast